INSR and PTPN2 |
insulin receptor |
protein tyrosine phosphatase, non-receptor type 2 |
- Insulin receptor signalling cascade
- IRS activation
- Signal attenuation
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- SHC activation
- Signaling by Insulin receptor
|
|
- Insulin Regular
- Insulin Lispro
- Insulin Glargine
- Insulin, porcine
- Mecasermin
- Insulin Aspart
- Insulin Detemir
- Insulin Glulisine
- Adenosine-5\'-[Beta, Gamma-Methylene]Triphosphate
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- Insulin, isophane
|
|
|
|
IRS1 and PRKCQ |
insulin receptor substrate 1 |
protein kinase C, theta |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- SOS-mediated signalling
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- IRS activation
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- G alpha (q) signalling events
- Signaling by GPCR
- Downstream TCR signaling
- Axon guidance
- Effects of PIP2 hydrolysis
- FCERI mediated NF-kB activation
- Inactivation, recovery and regulation of the phototransduction cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- The phototransduction cascade
- Programmed Cell Death
- G alpha (z) signalling events
- Netrin-1 signaling
- Innate Immune System
- Apoptotic cleavage of cellular proteins
- Apoptotic execution phase
- Diseases associated with visual transduction
- G alpha (q) signalling events
- GPCR downstream signaling
- TCR signaling
- Visual phototransduction
- Fc epsilon receptor (FCERI) signaling
- Platelet activation, signaling and aggregation
- Adaptive Immune System
|
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
|
- Staurosporine
- Phosphonothreonine
- Phosphonoserine
|
|
|
KCNJ11 and ABCC8 |
potassium channel, inwardly rectifying subfamily J, member 11 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
- Inwardly rectifying K+ channels
- Integration of energy metabolism
- ATP sensitive Potassium channels
- Regulation of insulin secretion
- Potassium Channels
|
- Inwardly rectifying K+ channels
- ABC-family proteins mediated transport
- Integration of energy metabolism
- ATP sensitive Potassium channels
- Regulation of insulin secretion
- Potassium Channels
|
- Glimepiride
- Ibutilide
- Verapamil
- Levosimendan
- Glyburide
- Diazoxide
- Thiamylal
|
- Adenosine triphosphate
- Glimepiride
- Chlorpropamide
- Nateglinide
- Repaglinide
- Glyburide
- Glipizide
- Gliclazide
- Tolbutamide
- Gliquidone
- Mitiglinide
- Glycodiazine
|
|
|
KIF11 and PPARG |
kinesin family member 11 |
peroxisome proliferator-activated receptor gamma |
- MHC class II antigen presentation
- Kinesins
- Factors involved in megakaryocyte development and platelet production
- Adaptive Immune System
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Adenosine-5\'-Diphosphate
- 3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol
- Monastrol
- (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE
- N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE
- (5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE
- (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
- [(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE
- (2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE
- (1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE
- (2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE
- (5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
NOTCH2 and DLL1 |
notch 2 |
delta-like 1 (Drosophila) |
- Notch-HLH transcription pathway
- Signaling by NOTCH2
- Generic Transcription Pathway
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Expression and Processing
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 Activation and Transmission of Signal to the Nucleus
|
- Signaling by NOTCH4
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Constitutive Signaling by NOTCH1 HD Domain Mutants
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Activated NOTCH1 Transmits Signal to the Nucleus
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Signaling by NOTCH3
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
|
|
|
|
PTPN2 and SRC |
protein tyrosine phosphatase, non-receptor type 2 |
SRC proto-oncogene, non-receptor tyrosine kinase |
|
|
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
SRC and HNF1A |
SRC proto-oncogene, non-receptor tyrosine kinase |
HNF1 homeobox A |
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
|
ABL1 and ERBB3 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
erb-b2 receptor tyrosine kinase 3 |
- Role of Abl in Robo-Slit signaling
- CDO in myogenesis
- Axon guidance
- Myogenesis
- Fcgamma receptor (FCGR) dependent phagocytosis
- Factors involved in megakaryocyte development and platelet production
- Signaling by Robo receptor
- Regulation of actin dynamics for phagocytic cup formation
- Innate Immune System
|
|
- Adenosine triphosphate
- Imatinib
- Dasatinib
- N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
- Nilotinib
- Bosutinib
- 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
- MYRISTIC ACID
- 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
- 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
- 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
- Regorafenib
- Ponatinib
|
|
|
|
ABL2 and ERBB3 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
erb-b2 receptor tyrosine kinase 3 |
- Role of Abl in Robo-Slit signaling
- Axon guidance
- Signaling by Robo receptor
|
|
- Adenosine triphosphate
- Dasatinib
- 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
|
|
|
|
ACHE and LAMA1 |
acetylcholinesterase (Yt blood group) |
laminin, alpha 1 |
- Synthesis of PC
- Peptide hormone metabolism
- Synthesis, secretion, and deacylation of Ghrelin
- Metabolism of lipids and lipoproteins
- Neurotransmitter Clearance In The Synaptic Cleft
- Phospholipid metabolism
- Glycerophospholipid biosynthesis
- Transmission across Chemical Synapses
|
- Axon guidance
- Laminin interactions
- ECM proteoglycans
- L1CAM interactions
- Non-integrin membrane-ECM interactions
|
- Choline
- Tacrine
- Gallamine Triethiodide
- Pyridostigmine
- Galantamine
- Isoflurophate
- Pralidoxime
- Minaprine
- Donepezil
- Demecarium
- Physostigmine
- Rivastigmine
- Edrophonium
- Ambenonium
- Tubocurarine
- Decamethonium
- Ephedrine
- Neostigmine
- Monoisopropylphosphorylserine
- Huperaine A
- Propidium
- 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium
- 3,6,9,12,15-Pentaoxaheptadecane
- 1-Deoxy-1-Thio-Heptaethylene Glycol
- (4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium
- Methylphosphonic Acid Ester Group
- Methylphosphinic Acid
- 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium
- Acetylcholine
- beta-L-fucose
- M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene
- 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
- 2-(N-Morpholino)-Ethanesulfonic Acid
- MF268
- 3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine
- 3-[(1s)-1-(Dimethylamino)Ethyl]Phenol
- (R)-tacrine(10)-hupyridone
- (S)-tacrine(10)-hupyridone
- TACRINE(8)-4-AMINOQUINOLINE
- (9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM
- 1-(2-nitrophenyl)-2,2,2-trifluoroethyl]-arsenocholine
- 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE
- 1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL
- (1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE
- 1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE
- 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM
- 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE
- 2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM
|
|
|
|
ACLY and CDKN2A |
ATP citrate lyase |
cyclin-dependent kinase inhibitor 2A |
- Fatty Acyl-CoA Biosynthesis
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Integration of energy metabolism
- ChREBP activates metabolic gene expression
- Triglyceride Biosynthesis
|
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- G1 Phase
- Cellular Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
- Oxidative Stress Induced Senescence
- Cellular Senescence
- Oncogene Induced Senescence
|
|
|
|
|
ACTB and CDKN2A |
actin, beta |
cyclin-dependent kinase inhibitor 2A |
- Axon guidance
- Gap junction degradation
- Adherens junctions interactions
- Translocation of GLUT4 to the plasma membrane
- L1CAM interactions
- Recycling pathway of L1
- HATs acetylate histones
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- Interaction between L1 and Ankyrins
- Cell-cell junction organization
- EPH-ephrin mediated repulsion of cells
- Prefoldin mediated transfer of substrate to CCT/TriC
- Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
- Gap junction trafficking and regulation
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Folding of actin by CCT/TriC
- Innate Immune System
- Cell junction organization
- Protein folding
- Formation of annular gap junctions
- Chromatin organization
- Gap junction trafficking
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- Signaling by VEGF
- Chaperonin-mediated protein folding
- Cell-extracellular matrix interactions
|
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- G1 Phase
- Cellular Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
- Oxidative Stress Induced Senescence
- Cellular Senescence
- Oncogene Induced Senescence
|
|
|
|
|
ACTG1 and CDKN2A |
actin gamma 1 |
cyclin-dependent kinase inhibitor 2A |
- Axon guidance
- Gap junction degradation
- Adherens junctions interactions
- Translocation of GLUT4 to the plasma membrane
- L1CAM interactions
- Recycling pathway of L1
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- Interaction between L1 and Ankyrins
- Cell-cell junction organization
- EPH-ephrin mediated repulsion of cells
- Gap junction trafficking and regulation
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Innate Immune System
- Cell junction organization
- Formation of annular gap junctions
- Gap junction trafficking
- Signaling by VEGF
- Cell-extracellular matrix interactions
|
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- G1 Phase
- Cellular Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
- Oxidative Stress Induced Senescence
- Cellular Senescence
- Oncogene Induced Senescence
|
|
|
|
|
ACTN4 and CDKN2A |
actinin, alpha 4 |
cyclin-dependent kinase inhibitor 2A |
- Response to elevated platelet cytosolic Ca2+
- Nephrin interactions
- Platelet degranulation
- Platelet activation, signaling and aggregation
|
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- G1 Phase
- Cellular Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
- Oxidative Stress Induced Senescence
- Cellular Senescence
- Oncogene Induced Senescence
|
|
|
|
|
AES and HNF1A |
amino-terminal enhancer of split |
HNF1 homeobox A |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by Wnt
- repression of WNT target genes
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- truncations of AMER1 destabilize the destruction complex
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|
JAG1 and NOTCH2 |
jagged 1 |
notch 2 |
- Signaling by NOTCH4
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Constitutive Signaling by NOTCH1 HD Domain Mutants
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Activated NOTCH1 Transmits Signal to the Nucleus
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Signaling by NOTCH3
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Notch-HLH transcription pathway
- Signaling by NOTCH2
- Generic Transcription Pathway
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Expression and Processing
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 Activation and Transmission of Signal to the Nucleus
|
|
|
|
|
AGTR2 and ERBB3 |
angiotensin II receptor, type 2 |
erb-b2 receptor tyrosine kinase 3 |
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- GPCR downstream signaling
- Peptide ligand-binding receptors
- Class A/1 (Rhodopsin-like receptors)
- G alpha (i) signalling events
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
|
|
|
|
|
|
NR0B1 and PPARG |
nuclear receptor subfamily 0, group B, member 1 |
peroxisome proliferator-activated receptor gamma |
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
AKT1 and PRKCQ |
v-akt murine thymoma viral oncogene homolog 1 |
protein kinase C, theta |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Activation of BH3-only proteins
- Signaling by Wnt
- Platelet Aggregation (Plug Formation)
- Signaling by EGFRvIII in Cancer
- AKT phosphorylates targets in the cytosol
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Regulation of beta-cell development
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- DAP12 interactions
- Regulation of mRNA stability by proteins that bind AU-rich elements
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Activation of BAD and translocation to mitochondria
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by VEGF
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Regulation of gene expression in beta cells
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- Translocation of GLUT4 to the plasma membrane
- deactivation of the beta-catenin transactivating complex
- VEGFA-VEGFR2 Pathway
- Metabolism of nitric oxide
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- VEGFR2 mediated vascular permeability
- Downstream signaling of activated FGFR
- Programmed Cell Death
- XAV939 inhibits tankyrase, stabilizing AXIN
- eNOS activation and regulation
- Intrinsic Pathway for Apoptosis
- Butyrate Response Factor 1 (BRF1) destabilizes mRNA
- Innate Immune System
- Signalling by NGF
- CTLA4 inhibitory signaling
- AKT-mediated inactivation of FOXO1A
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Negative regulation of the PI3K/AKT network
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- eNOS activation
- TCF dependent signaling in response to WNT
- KSRP destabilizes mRNA
- GPVI-mediated activation cascade
- Signaling by WNT in cancer
|
- G alpha (q) signalling events
- Signaling by GPCR
- Downstream TCR signaling
- Axon guidance
- Effects of PIP2 hydrolysis
- FCERI mediated NF-kB activation
- Inactivation, recovery and regulation of the phototransduction cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- The phototransduction cascade
- Programmed Cell Death
- G alpha (z) signalling events
- Netrin-1 signaling
- Innate Immune System
- Apoptotic cleavage of cellular proteins
- Apoptotic execution phase
- Diseases associated with visual transduction
- G alpha (q) signalling events
- GPCR downstream signaling
- TCR signaling
- Visual phototransduction
- Fc epsilon receptor (FCERI) signaling
- Platelet activation, signaling and aggregation
- Adaptive Immune System
|
- Adenosine triphosphate
- Arsenic trioxide
- Inositol 1,3,4,5-Tetrakisphosphate
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
|
- Staurosporine
- Phosphonothreonine
- Phosphonoserine
|
|
|
ALB and HNF1A |
albumin |
HNF1 homeobox A |
- Lipoprotein metabolism
- Bile acid and bile salt metabolism
- Metabolism of lipids and lipoproteins
- Recycling of bile acids and salts
- Platelet degranulation
- Lipid digestion, mobilization, and transport
- Transport of organic anions
- SLC-mediated transmembrane transport
- HDL-mediated lipid transport
- Scavenging of heme from plasma
- Response to elevated platelet cytosolic Ca2+
- Platelet activation, signaling and aggregation
- Transport of vitamins, nucleosides, and related molecules
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|